How To Invest: 3-Month Relative Strength Rating Reacts Faster To Stock Moves
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
03-07-2025
- Business Insider
Disney Stock Rides High as Analysts Say ‘Profits Are Back & Bigger than Ever'
Disney stock (DIS) has surged to new 52-week highs, with Jefferies upgrading the stock to Buy and pointing to strong tailwinds in parks, streaming, and cruises. Investor excitement is growing ahead of a packed July calendar, which includes fresh Marvel releases, new cruise rollouts, and the company's earnings report. Web traffic for Disney+ is soaring, and theme park bookings are beating expectations. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Disney Stock Breaks Out as Technical Signals Flash Green The technical setup looks strong. Disney stock is consolidating near $124, and analysts are watching for a breakout. The IBD Composite Rating has climbed to 94 out of 99, and the stock's relative strength line has hit fresh highs. It's trading well above key moving averages, signalling momentum that could carry into earnings. Jefferies Analyst Sees $144 Price Target and Strong Growth Ahead James Heaney, CFA at Jefferies, upgraded Disney to Buy with a new price target of $144. His bullish case is based on accelerating revenue in the Parks and Experiences division, cruise expansion with two new ships, and improving Direct-to-Consumer (DTC) margins. Heaney expects the cruise business alone could add over $1 billion in revenue. Meanwhile, Disney's content slate including Zootopia 2 and Avatar 3, alongside ESPN's DTC launch, creates further upside. Heaney is a 5-star TipRanks analyst with a 20.2% average return and a 51% success rate. Bank of America Adds Fuel With $140 Target Jessica Reif Ehrlich at Bank of America Securities also maintained a Buy rating with a $140 price target in a report issued June 27. Her optimism is rooted in sequential improvements in the Parks and Experiences division, led by two new cruise ships expected to drive long-term revenue gains. She also flagged strength in the sports advertising sector and ongoing margin improvements in the DTC business. Ehrlich sees Disney's 2025 earnings per share guidance as realistic, with the parks segment expected to provide the foundational strength while DTC investment continues. Despite some box office underperformance, the analyst expects profitability to rise, supported by upcoming releases and a strengthened content pipeline. Investor Exit Draws Headlines but Not Panic Former Marvel chairman Ike Perlmutter reportedly sold his entire Disney stake, calling for a stock decline. But his exit hasn't stopped the rally. Analysts say recent moves suggest institutional support is still strong, and technicals remain bullish. Is Disney Stock a Good Buy? Analysts are firmly in Disney's corner. Out of 19 Wall Street analysts covering the stock over the past three months, 16 rate it a Buy, while three recommend Hold. No analysts suggest selling the stock. The average 12-month DIS price target is $129.24, implying a 4.66% upside from the current price of $123.49.
Business Upturn
23-06-2025
- Business Upturn
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
Sydney, Australia: As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech's analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highlights from the report include: A growing pipeline of preclinical and Phase I–II LBP candidates, with notable concentration in Alzheimer's, IBD, diabetes, and NASH. Over 90 industry-sponsored trials launched since 2020, yet 32% have experienced discontinuation. North America and Europe leading in regulatory approvals and manufacturing activity, with rising interest from biotechs in Asia-Pacific. A projected CAGR of 38% for the LBP and microbiome CDMO market through 2030. The global market for LBPs and microbiome contract development and manufacturing organizations (CDMOs) was valued at USD 31.84 million in 2023. With growing investment in players like Vedanta Biosciences and MaaT Pharma, the LBP field is maturing but also becoming more competitive. Success will depend on smart trial design, global regulatory navigation, and efficient feasibility execution. Drawing on deep therapeutic expertise in microbiome-related studies and gastrointestinal, metabolic, and immunologic indications, Novotech supports sponsors from early development through global trial delivery. With operations spanning Asia-Pacific, North America, and Europe, Novotech is uniquely positioned to help biotech and small to mid-size pharma companies translate LBP potential into clinical success. Download the full white paper 'Why Live Biotherapeutics Matter to Emerging Biotech' here. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
17-06-2025
- Yahoo
IBD Stock Of The Day: Cisco Tests Buy Point, 'Getting On The Right Side Of AI'
Cisco Systems, IBD Stock Of The Day, is flirting with a buy point as the old tech giant gains traction as an AI infrastructure provider.
